Glenmark Pharmaceuticals Limited reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported sales was INR 30,160.07 million compared to INR 29,583.66 million a year ago. Revenue was INR 38,361.17 million compared to INR 29,580.89 million a year ago.

Net loss was INR 12,182.79 million compared to INR 4,283.03 million a year ago. Basic loss per share from continuing operations was INR 44.04 compared to INR 20.37 a year ago. Diluted loss per share from continuing operations was INR 44.04 compared to INR 20.37 a year ago.

Basic loss per share was INR 43.17 compared to INR 15.18 a year ago. Diluted loss per share was INR 43.17 compared to INR 15.18 a year ago.